A newly posted European assessment of Mounjaro answers a question that a drug’s indication list can leave unresolved: can regulators recognize heart-related benefit without granting a separate heart-risk indication? For tirzepatide in adults with type 2 diabetes and established cardiovascular disease, EMA’s answer was yes.
The EMA product page lists the detailed assessment report as first published on October 8, 2026. The assessment itself is dated June 25, and EMA explained the outcome publicly on June 26. This is a closer look at newly available regulatory reasoning, not an announcement of a new October approval.
Why a separate indication was not needed
Lilly requested an additional indication for reducing major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. In its June explanation, EMA said those patients were already covered by Mounjaro’s approved diabetes indication. Its human medicines committee, CHMP, therefore considered a separate indication unnecessary.
The detailed assessment makes the reasoning explicit: preventing cardiovascular events is an important aim of diabetes treatment. The committee acknowledged cardioprotection while declining the proposed standalone wording. Reading that outcome as a rejection of all cardiovascular benefit would miss the distinction between evidence and how an indication is written.
The current EU product information reflects that approach. Its diabetes indication points readers to cardiovascular-event results, and section 5.1 describes SURPASS-CVOT. Adult weight management remains a separate indication with its own eligibility criteria. Our Zepbound and Mounjaro comparison explains why brand and country both matter when interpreting approved uses.
What SURPASS-CVOT actually compared
This was a randomized, double-blind trial in adults with inadequately controlled type 2 diabetes, established cardiovascular disease and a BMI of at least 25. The comparison was tirzepatide versus dulaglutide, another active diabetes treatment, with both added to standard care. It was not a placebo-controlled obesity trial.
The research regimens were once-weekly tirzepatide at a maximum tolerated dose up to 15 mg and once-weekly dulaglutide 1.5 mg. These identify the study comparison, not doses for an individual reader. Median follow-up was about four years. Of 13,299 randomized participants, 13,165 entered the modified intention-to-treat analysis after 134 people randomized in error were excluded, according to the assessment.
The main outcome was time to a first cardiovascular death, heart attack or stroke. EMA considered the primary analysis consistent with a treatment-policy approach to treatment interruptions and discontinuations, although it noted that an estimand had not been explicitly defined. That nuance matters: this was not simply an analysis of people who stayed on treatment perfectly. Our guide to trial estimands explains how the analysis question shapes a result.
Noninferiority is meaningful—but is not superiority
The primary event occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group. The hazard ratio was 0.92, with a 95.3% confidence interval of 0.83–1.01. The unusual confidence level reflects the trial’s statistical testing plan; it should not be silently relabeled as 95%.
The interval’s upper end was below the prespecified noninferiority boundary of 1.05. Tirzepatide therefore met the trial’s criterion for not being worse than dulaglutide beyond the allowed margin. Dulaglutide had previously demonstrated cardiovascular benefit against placebo, which helps explain why this active-treatment comparison was clinically useful.
However, the interval crossed 1.0, and the superiority test did not succeed. The numerically lower event proportion is not proof that tirzepatide prevents more cardiovascular events than dulaglutide. The percentages summarize participants with events during follow-up; the hazard ratio describes the time-to-event comparison. They should not be treated as interchangeable measures.
That unsuccessful superiority step also limited later claims. The report says statistical results for key secondary endpoints were nominal rather than protected by the planned control for multiple testing. Interesting mortality or kidney findings therefore should not be promoted to the same confirmatory status as the primary noninferiority result. The trial-reading guide offers a checklist for recognizing this distinction.
An indirect placebo estimate is a different kind of evidence
The assessment also examined an indirect comparison that combined SURPASS-CVOT with data from the earlier REWIND dulaglutide trial. Such an analysis can estimate how tirzepatide might compare with placebo, but it does not create a randomized tirzepatide–placebo arm within SURPASS-CVOT.
EMA treated that analysis as supportive, not definitive, because indirect comparisons can introduce bias. The report did not support including those indirect estimates in section 5.1. For readers encountering a larger placebo-relative benefit elsewhere, the first question is which comparison produced it—not whether it is a more impressive version of the direct result.
What this means for readers following weight-loss treatment
The population sets an essential boundary. These cardiovascular findings concern people with diabetes and established cardiovascular disease; they cannot establish the same benefit in people taking tirzepatide solely for weight management without diabetes. The tirzepatide profile connects the medicine to its broader evidence without making those populations interchangeable.
Benefit also does not remove treatment burdens. EMA’s assessment describes gastrointestinal adverse effects as the main tolerability issue and discusses pancreatitis, gallbladder problems and diabetic retinopathy among the relevant safety concerns. It judged the overall benefit–risk balance positive, not risk-free.
A useful treatment discussion asks which indication applies, which health outcome matters, and how safety and existing cardiovascular care will be monitored together. This report helps explain the evidence behind that conversation. It does not supply a reason to switch medicines, change doses or replace other cardiovascular treatment independently.


